Cargando…
Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959046/ https://www.ncbi.nlm.nih.gov/pubmed/27457763 http://dx.doi.org/10.1186/s12885-016-2559-8 |
| _version_ | 1782444362560438272 |
|---|---|
| author | Adenis, Antoine de la Fouchardiere, Christelle Paule, Bernard Burtin, Pascal Tougeron, David Wallet, Jennifer Dourthe, Louis-Marie Etienne, Pierre-Luc Mineur, Laurent Clisant, Stéphanie Phelip, Jean-Marc Kramar, Andrew Andre, Thierry |
| author_facet | Adenis, Antoine de la Fouchardiere, Christelle Paule, Bernard Burtin, Pascal Tougeron, David Wallet, Jennifer Dourthe, Louis-Marie Etienne, Pierre-Luc Mineur, Laurent Clisant, Stéphanie Phelip, Jean-Marc Kramar, Andrew Andre, Thierry |
| author_sort | Adenis, Antoine |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4959046 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-49590462016-07-26 Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program Adenis, Antoine de la Fouchardiere, Christelle Paule, Bernard Burtin, Pascal Tougeron, David Wallet, Jennifer Dourthe, Louis-Marie Etienne, Pierre-Luc Mineur, Laurent Clisant, Stéphanie Phelip, Jean-Marc Kramar, Andrew Andre, Thierry BMC Cancer Erratum BioMed Central 2016-07-25 /pmc/articles/PMC4959046/ /pubmed/27457763 http://dx.doi.org/10.1186/s12885-016-2559-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Erratum Adenis, Antoine de la Fouchardiere, Christelle Paule, Bernard Burtin, Pascal Tougeron, David Wallet, Jennifer Dourthe, Louis-Marie Etienne, Pierre-Luc Mineur, Laurent Clisant, Stéphanie Phelip, Jean-Marc Kramar, Andrew Andre, Thierry Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program |
| title | Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program |
| title_full | Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program |
| title_fullStr | Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program |
| title_full_unstemmed | Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program |
| title_short | Erratum to: Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program |
| title_sort | erratum to: survival, safety, and prognostic factors for outcome with regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (rebecca) nested within a compassionate use program |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959046/ https://www.ncbi.nlm.nih.gov/pubmed/27457763 http://dx.doi.org/10.1186/s12885-016-2559-8 |
| work_keys_str_mv | AT adenisantoine erratumtosurvivalsafetyandprognosticfactorsforoutcomewithregorafenibinpatientswithmetastaticcolorectalcancerrefractorytostandardtherapiesresultsfromamulticenterstudyrebeccanestedwithinacompassionateuseprogram AT delafouchardierechristelle erratumtosurvivalsafetyandprognosticfactorsforoutcomewithregorafenibinpatientswithmetastaticcolorectalcancerrefractorytostandardtherapiesresultsfromamulticenterstudyrebeccanestedwithinacompassionateuseprogram AT paulebernard erratumtosurvivalsafetyandprognosticfactorsforoutcomewithregorafenibinpatientswithmetastaticcolorectalcancerrefractorytostandardtherapiesresultsfromamulticenterstudyrebeccanestedwithinacompassionateuseprogram AT burtinpascal erratumtosurvivalsafetyandprognosticfactorsforoutcomewithregorafenibinpatientswithmetastaticcolorectalcancerrefractorytostandardtherapiesresultsfromamulticenterstudyrebeccanestedwithinacompassionateuseprogram AT tougerondavid erratumtosurvivalsafetyandprognosticfactorsforoutcomewithregorafenibinpatientswithmetastaticcolorectalcancerrefractorytostandardtherapiesresultsfromamulticenterstudyrebeccanestedwithinacompassionateuseprogram AT walletjennifer erratumtosurvivalsafetyandprognosticfactorsforoutcomewithregorafenibinpatientswithmetastaticcolorectalcancerrefractorytostandardtherapiesresultsfromamulticenterstudyrebeccanestedwithinacompassionateuseprogram AT dourthelouismarie erratumtosurvivalsafetyandprognosticfactorsforoutcomewithregorafenibinpatientswithmetastaticcolorectalcancerrefractorytostandardtherapiesresultsfromamulticenterstudyrebeccanestedwithinacompassionateuseprogram AT etiennepierreluc erratumtosurvivalsafetyandprognosticfactorsforoutcomewithregorafenibinpatientswithmetastaticcolorectalcancerrefractorytostandardtherapiesresultsfromamulticenterstudyrebeccanestedwithinacompassionateuseprogram AT mineurlaurent erratumtosurvivalsafetyandprognosticfactorsforoutcomewithregorafenibinpatientswithmetastaticcolorectalcancerrefractorytostandardtherapiesresultsfromamulticenterstudyrebeccanestedwithinacompassionateuseprogram AT clisantstephanie erratumtosurvivalsafetyandprognosticfactorsforoutcomewithregorafenibinpatientswithmetastaticcolorectalcancerrefractorytostandardtherapiesresultsfromamulticenterstudyrebeccanestedwithinacompassionateuseprogram AT phelipjeanmarc erratumtosurvivalsafetyandprognosticfactorsforoutcomewithregorafenibinpatientswithmetastaticcolorectalcancerrefractorytostandardtherapiesresultsfromamulticenterstudyrebeccanestedwithinacompassionateuseprogram AT kramarandrew erratumtosurvivalsafetyandprognosticfactorsforoutcomewithregorafenibinpatientswithmetastaticcolorectalcancerrefractorytostandardtherapiesresultsfromamulticenterstudyrebeccanestedwithinacompassionateuseprogram AT andrethierry erratumtosurvivalsafetyandprognosticfactorsforoutcomewithregorafenibinpatientswithmetastaticcolorectalcancerrefractorytostandardtherapiesresultsfromamulticenterstudyrebeccanestedwithinacompassionateuseprogram |